This trial will study a new cancer treatment involving CAR-T cells, which are genetically modified to target and destroy cancer cells. The safety and effectiveness of this treatment will be evaluated in patients with B cell acute lymphoblastic leukemia.
3 Primary · 5 Secondary · Reporting Duration: 40 months
24 Total Participants · 6 Treatment Groups
Primary Treatment: CAR-20/19-T cells · No Placebo Group · Phase 1
Age 1 - 39 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: